RAIN - Rain Therapeutics to Present at SVB Leerink Global Healthcare Conference

NEWARK, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will provide a corporate overview followed by a moderated Q&A at the virtual SVB Leerink 11 ^th Annual Global Healthcare Conference on Friday, February 18 ^th at 1:40 pm ET.

Additional details can be found below:

Conference: SVB Leerink Global Healthcare Conference
Date and Time: Friday, February 18 ^th at 1:40 pm ET.
Registration: Webcast link here .

Replay of the corporate overview presentation and Q&A will be available by visiting the " Events " section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
jtemperato@lifescicomms.com

Investor Contact
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com